@article{de96c12dbc294c54b54cfab4eb9fbc1e,
title = "Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary",
abstract = "The purpose of this work is to identify and synthesize research produced since the second edition of these Guidelines was published and incorporate new results into revised evidence-based recommendations for the treatment of severe traumatic brain injury in pediatric patients. This document provides an overview of our process, lists the new research added, and includes the revised recommendations. Recommendations are only provided when there is supporting evidence. This update includes 22 recommendations, 9 are new or revised from previous editions. New recommendations on neuroimaging, hyperosmolar therapy, analgesics and sedatives, seizure prophylaxis, temperature control/hypothermia, and nutrition are provided. None are level I, 3 are level II, and 19 are level III. The Clinical Investigators responsible for these Guidelines also created a companion algorithm that supplements the recommendations with expert consensus where evidence is not available and organizes possible interventions into first and second tier utilization. The complete guideline document and supplemental appendices are available electronically (https://doi.org/10.1097/PCC.0000000000001735). The online documents contain summaries and evaluations of all the studies considered, including those from prior editions, and more detailed information on our methodology. New level II and level III evidence-based recommendations and an algorithm provide additional guidance for the development of local protocols to treat pediatric patients with severe traumatic brain injury. Our intention is to identify and institute a sustainable process to update these Guidelines as new evidence becomes available.",
keywords = "Critical care, Evidence-based medicine, Guidelines, Head injury, Pediatrics, Systematic review, Traumatic brain injury",
author = "Kochanek, {Patrick M.} and Tasker, {Robert C.} and Nancy Carney and Totten, {Annette M.} and Adelson, {P. David} and Selden, {Nathan R.} and Cynthia Davis-O'Reilly and Hart, {Erica L.} and Bell, {Michael J.} and Bratton, {Susan L.} and Grant, {Gerald A.} and Niranjan Kissoon and Reuter-Rice, {Karin E.} and Vavilala, {Monica S.} and Wainwright, {Mark S.}",
note = "Funding Information: Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to Stanford University (W911 QY-14-C-0086) and a subcontract awarded to Oregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation. Dr Kochanek received funding from the Society of Critical Care Medicine (Editor-in-Chief of Pediatric Critical Care Medicine), from serving as an expert witness on cases in pediatric critical care. Drs Carney and Totten{\textquoteright}s, Ms Davis-O{\textquoteright}Reilly{\textquoteright}s, and Ms Hart{\textquoteright}s institutions received funding from Stanford University. Dr Selden disclosed that he has stock options (current $0 value) in Cerebrotech for scientific advisory board service (this device is not clinically available and is not referenced in the work). Dr Reuter-Rice received funding from textbook royalties and curriculum content, and she received support for article research from Robert Wood Johnson Foundation funding 2013–2016. Dr Wainwright received funding from Sage Therapeutics. The remaining authors have disclosed that they do not have any potential conflicts of interest. Funding Information: Supported, in part, by the U.S. Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, through a contract awarded to Stanford University (W911QY-14-C-0086) and a subcontract awarded to Oregon Health & Science University. Prior editions were supported, in part, by funding from multiple sources through the Brain Trauma Foundation. Dr Kochanek received funding from the Society of Critical Care Medicine (Editor-in-Chief of Pediatric Critical Care Medicine), from serving as an expert witness on cases in pediatric critical care.DrsCarney and Totten's, MsDavis-O'Reilly's, and MsHart's institutions received funding from Stanford University. Dr Selden disclosed that he has stock options (current $0 value) in Cerebrotech for scientific advisory board service (this device is not clinically available and is not referenced in the work). Dr Reuter-Rice received funding from textbook royalties and curriculum content, and she received support for article research from Robert Wood Johnson Foundation funding 2013-2016. Dr Wainwright received funding from Sage Therapeutics. The remaining authors have disclosed that they do not have any potential conflicts of interest. Publisher Copyright: {\textcopyright} 2019 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.",
year = "2019",
month = jun,
day = "1",
doi = "10.1093/neuros/nyz051",
language = "English (US)",
volume = "84",
pages = "1169--1178",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "6",
}